Early Vaccine Data on OmicronDec 8, 2021
With early data in on the Omicron variant, biotechnology analyst Matthew Harrison takes us through where we stand on vaccine efficacy headed into the winter.
As nations and the healthcare industry work to contain COVID-19, investors search for clarity on what’s next. Morgan Stanley analysts and economists share insights on the road ahead.
Will pent-up demand for experiences mean boom times ahead for travel & leisure? Hilton CEO Chris Nassetta sits down for an exclusive interview with Morgan Stanley’s Thomas Allen to discuss the future of travel post-COVID.
Sign up to get Morgan Stanley Ideas delivered to your inbox.
*Invalid email address
Thank You for Subscribing!
Would you like to help us improve our coverage of topics that might interest you? Tell us about yourself.
As cyber threats follow enterprises into the cloud, two key software markets are set to converge into a single discipline for more effective threat prevention, detection and response. A look at the opportunities for investors.